Aclarion, INC 8-K filings

Aclarion, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of seven directors and the approval of key corporate proposals.

Aclarion, Inc. announced its Board of Directors has authorized a share repurchase program of up to $2.5 million of its outstanding common stock over the next 12 months.

Aclarion, Inc. has adopted a limited duration stockholder rights plan to protect long-term shareholder value and ensure the Board has time for informed decisions.

Aclarion, Inc. announced the closing of a $10.4 million common stock financing, strengthening its balance sheet and extending its cash runway into 2028.

Aclarion, Inc. announced a registered direct offering of common stock and pre-funded warrants, expecting to raise approximately $10.36 million for market and product development.

Aclarion, Inc. announced a registered direct offering of common stock and pre-funded warrants, raising approximately $2.5 million to fund market and product development, and clinical trials.

Aclarion, Inc. announced the appointment of seasoned finance executive Gregory A. Gould as its new Chief Financial Officer, effective September 1, 2025.

Aclarion, Inc. stockholders approved a proposed reverse stock split and the election of seven directors, but rejected an amendment to the company's 2022 equity incentive plan at their reconvened 2025 Annual Meeting.

Aclarion, Inc. has adjourned its Annual Meeting of Stockholders to July 21, 2025, to allow for the solicitation of additional votes on proposals.

Aclarion, Inc. announced that Chief Financial Officer John Lorbiecki will retire, with a search for his replacement initiated and a transition period planned.

Aclarion, Inc. announces the release of an updated investor presentation in conjunction with its appearance at the Planet MicroCap Showcase: VEGAS 2025, highlighting strategic and financial updates.

Aclarion, Inc. executed a 1-for-27 reverse stock split of its common stock, effective March 27, 2025, to comply with Nasdaq listing requirements.

Aclarion, Inc. reports a $15.2 million cash balance, achieving compliance with Nasdaq's minimum stockholders' equity requirement.

Aclarion Inc. announces the successful approval of three key proposals, including an increase in authorized shares and warrant issuance, at its Special Meeting of Stockholders held on March 5, 2025.

Aclarion, Inc. has adjourned its Special Meeting of Stockholders to March 5, 2025, to solicit additional votes regarding proposals outlined in the definitive proxy statement.

Aclarion, Inc. has announced a registered direct offering of 506,803 shares of common stock at $9.25 per share, expected to generate approximately $4.7 million in gross proceeds.

Aclarion, Inc. announces a reverse stock split and successful public offering, leading to expected compliance with Nasdaq's minimum equity requirement.

Aclarion Inc. has successfully completed a public offering, raising approximately $13.3 million and issuing multiple series of warrants.

Aclarion, Inc. has announced a registered direct offering of 3,380,276 shares of common stock at $0.142 per share, expected to generate approximately $0.5 million in gross proceeds.

Aclarion, Inc. has terminated its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, effective immediately.

Aclarion Inc. held its 2024 Annual Meeting of Stockholders on December 31, 2024, where all proposals, including the election of directors and a reverse stock split, were approved.

Aclarion, Inc. has amended its equity line purchase agreement with White Lion Capital, extending the agreement's term to December 31, 2025, and introducing two new methods for pricing share sales.

Aclarion, Inc. received a delisting notice from Nasdaq after failing to regain compliance with the minimum bid price requirement, and is also under review for not meeting the minimum stockholders' equity requirement.

Aclarion, Inc. has entered into a securities purchase agreement for a $1 million financing through the issuance of convertible preferred stock and warrants.

Aclarion Inc. has entered into an agreement with Ascendiant Capital Markets to sell up to $10 million of its common stock through an at-the-market offering.

Aclarion Inc. stockholders have approved a proposal granting the board discretionary authority to enact a reverse stock split within a range of 1-for-5 to 1-for-50.

Aclarion Inc. has entered into agreements to issue warrants and common stock to accredited investors, raising $290,000 in gross proceeds.

Aclarion, Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting only $1,642,177 as of June 30, 2024.

Aclarion, Inc. has issued 1,000 shares of Series B Convertible Preferred Stock in exchange for approximately $930,000 of outstanding senior notes and accrued interest.

Aclarion Inc. filed an amended 8-K to correct a clerical error in a subscription agreement exhibit, related to a recent $116,000 stock sale.